

Friday 2 January 2009

Lifeline Scientific, Inc
("Lifeline" or "the Company")

Trial Results Published

New England Journal of Medicine Publishes Landmark Trial Results

Lifeline Scientific, the medical technology company focused on commercialising its LifePort® Kidney Transporter, welcomes yesterday's publication of landmark trial results in The New England Journal of Medicine. LifePort is an advanced organ preservation and transport system designed to address the global challenge of human donor organ shortages.

The Company will announce full details of this landmark trial, the first randomised, prospective trial to compare the preservation of kidneys for transplant by machine and by the traditional box of ice, on Monday.

Enquiries

Lifeline Scientific, Inc.	
David Kravitz, CEO	
Seymour Pierce (Nomad)	+44 (0)20 7107 8000
Mark Percy / Huaizheng Peng / Sarah Jacobs	
Financial Dynamics	+44 (0)20 7831 3113
Ben Brewerton / John Dineen	

About the LifePort Kidney Transporter

Created with the challenges of organ recovery and transport in mind, LifePort Kidney Transporter is designed to provide improved kidney preservation, evaluation and transport prior to transplantation. LifePort provides a sealed, sterile, protected environment where a solution is gently pumped through the kidney at cold temperatures to minimize damage while the organ is outside the body. LifePort is lightweight and portable, allowing organs to be perfused from the time of recovery until transplant. It is designed to travel unaccompanied by land or air, safely transporting the kidneys across town or between countries. While the kidney is being perfused, the LifePort records data on temperature, flow rate vascular resistance and pressure every 10 seconds providing surgeons with additional data prior to transplant. During its pilot introduction, approximately 280 LifePorts have been installed in 81 transplant programmes worldwide treating more than 12,000 kidneys.

About Lifeline Scientific Inc.

Lifeline Scientific, Inc. is a Chicago-based global medical technology company with European headquarters located in Brussels. Its primary focus is to commercialise its FDA approved, CE marked, clinically validated and revenue generating LifePort Kidney Transporter. Devices for preservation of the heart, lung pancreas and liver are in late stage pre-clinical development.